Horn Howard sold $117K of RARE
Horn Howard (Chief Financial Officer) sold 4,696 shares of Ultragenyx Pharmaceutical Inc. (RARE) at $24.92 ($0.12M total) on 2026-08-03 under a Rule 10b5-1 trading plan.
How this was made
The 30-second read
Why it matters
The newest fact is the CFO’s planned open-market sale amount, price, and post-transaction holdings. It can be used for sentiment monitoring but does not introduce new fundamentals in the provided text.
Market read
Traders may note insider selling, but the 10b5-1 framing suggests limited incremental information content.
What to watch
The article provides only the sale details; it does not include any offsetting insider buys, changes in guidance, or operational/clinical updates that would justify a stronger trading view.
Background
The article is a SEC Form 4 insider transaction disclosure for Ultragenyx Pharmaceutical Inc.
Ticker impact
Ultragenyx CFO Horn Howard filed a Form 4 showing an open-market sale of 4,696 shares at $24.92 on Aug 3 under a 10b5-1 plan.
Low likelihood of a sustained price move; any reaction is likely limited and short-lived.
The filing is a routine 10b5-1 planned sale by the CFO, with no accompanying guidance, deal, or regulatory/clinical catalyst in the text.
Market effects
Minimal. Insider 10b5-1 sales are common and do not, by themselves, signal sector-wide changes.
None indicated.
None indicated.
Counterpoint
Because the sale is explicitly under a pre-arranged 10b5-1 plan, it may reflect liquidity planning rather than bearish expectations.
Key entities
- issuerUltragenyx Pharmaceutical Inc.
Subject of the Form 4 insider transaction disclosure.
- insiderHorn Howard
Chief Financial Officer who sold shares under a 10b5-1 plan.